News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Protalex, Inc. (PRTX) Receives Third Interim Review from Independent Data Safety Monitoring Committee in its Phase 1b Trial of PRTX-100 in Rheumatoid Arthritis


7/23/2013 9:34:18 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SUMMIT, N.J.--(BUSINESS WIRE)--Protalex, Inc. (OTCBB: PRTX), a clinical-stage biopharmaceutical company, today announced that following a planned interim safety review by its Independent Data Safety Monitoring Committee (SMC), the Company is continuing enrollment in its multicenter Phase 1b randomized, multiple-dose, dose-escalation study of PRTX-100 in combination with methotrexate or leflunomide in adults with active rheumatoid arthritis (RA). PRTX-100 is a candidate drug incorporating a highly-purified form of Staphylococcal Protein A.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES